‹ Back

MedTech Industry Pulse: March 2026 Roundup

March 2026  |  By Cahir Solutions

March brought a strong mix of regulatory, market, and regional developments for MedTech teams to watch. The month’s standout theme was clearer regulatory expectations, especially as the FDA finalized guidance for weight-loss devices and the QMSR transition moved into implementation mode. (Read More   )

 

 

US regulatory focus

 

The FDA issued final guidance for medical devices with weight-loss or weight-management indications, outlining expectations for non-clinical testing, clinical study design, and benefit-risk analysis across PMA, 510(k), De Novo, and IDE pathways. For companies developing obesity-related technologies, this signals a higher bar for evidence generation, labeling, and submission readiness.
The QMSR transition also entered its active phase, meaning manufacturers should now be focused on implementation readiness and inspection preparedness under the FDA’s updated quality framework aligned with ISO 13485. In practical terms, quality systems, documentation, and audit readiness are no longer future priorities — they are current execution items. (Read More  )

 

Global regulatory updates

In Europe and Switzerland, the updated Mutual Recognition Agreement was a notable step toward more predictable market access and regulatory cooperation. At the same time, Team-NB highlighted that the MDR/IVDR revision must not weaken patient safety or market surveillance.
In the UK, the MHRA updated its regulatory advice request process, emphasizing early planning and structured submissions for devices seeking guidance. Across Asia, China’s NMPA continued tightening expectations for innovative-device trial protocols, while Malaysia and Singapore extended their regulatory reliance pilot, reinforcing a broader global push for efficiency and harmonization.

 

What this means

For MedTech stakeholders, March’s news underscores a common message: regulators are asking for stronger evidence, clearer study design, and more disciplined quality systems. That affects product strategy, clinical development, regulatory planning, and go-to-market timing all at once.

 

Thank you for reading this month’s edition. We’ll be back in April with the latest updates, insights, and developments in MedTech and Digital Health. Until then, stay well and be safe.

 

How CAHIR Solutions can help
CAHIR Solutions can help teams respond to these shifts by strengthening regulatory strategy, tightening submission narratives, and aligning development plans with FDA and global expectations. For organizations working on weight-loss, obesity, or other high-scrutiny devices, CAHIR can support gap assessments, evidence planning, documentation readiness, and cross-functional execution so programs move forward with more confidence and less friction. Please reach out to us at info@cahir.ai